A new supplement category has appeared almost overnight:
GLP-1 support.
Protein blends, muscle-preservation capsules, electrolyte mixes, and anti-nausea formulas, all pitched to the millions of people now taking semaglutide or tirzepatide. The premise is that these drugs do something to your body that needs correcting, and that a supplement is the way to correct it.
It’s worth asking the obvious question before buying anything:
Is that premise true?
The marketing rests almost entirely on two alarming-sounding statistics. One is about muscle. The other is about side effects. Both numbers are real. And both, once you read past the headline, tell a much calmer story than the products built on them suggest.
Why GLP-1 Support Became a Gold Rush
Before dismantling the numbers, it’s worth understanding why this category appeared so fast. It sits at the intersection of a genuine medical phenomenon and an enormous commercial opportunity.
GLP-1 prescriptions have grown several hundred percent in just a few years, creating millions of anxious new customers almost overnight. These are people who are spending significant money on a powerful drug, hearing frightening things about muscle loss on social media, and feeling real if usually mild side effects during their first weeks.
That combination of money, worry, and physical sensation is precisely the soil in which a supplement market grows fastest. Products making GLP-1-related claims have expanded at a triple-digit annual rate.
The industry didn’t invent the concerns it sells against.
Muscle loss and nausea are real. What it did was take two legitimate findings and amplify their scariest framing, because alarm sells better than context. Understanding the actual data is the antidote, so it’s worth taking each number in turn.
The Number That Launched an Industry
Start with the statistic doing most of the work.
On a GLP-1 drug, up to 45 percent of the weight you lose is not fat but lean mass, including muscle.
That figure is genuine. In the STEP 1 trial of semaglutide, participants lost about 15 percent of their body weight. Roughly 45 percent of that loss came from lean tissue measured on DXA. Tirzepatide trials land somewhat lower, closer to 25 percent. Across the research, lean mass accounts for something like a quarter to nearly half of total weight lost. Stated plainly, that sounds like a catastrophe unfolding inside every person on these medications.
It’s the emotional engine of the entire GLP-1 support market.
Here’s the context the marketing leaves out. That ratio is completely normal for rapid weight loss of any kind. When people lose weight through dieting, bariatric surgery, or any method that sheds pounds quickly, lean mass typically accounts for 20 to 50 percent of what’s lost.
This is sometimes called the “quarter fat-free mass rule.” GLP-1 drugs sit squarely within the expected range rather than outside it. The mechanism isn’t some sinister property unique to these medications.
It’s simply what happens when a body gets smaller.
Why the Scary Framing Misleads
The lean-mass number is misleading in a second, more important way. It describes a proportion, not an outcome. And the outcome is mostly good.
Because fat is lost faster than lean tissue, body composition generally improves on these drugs. A person finishes treatment with a lower percentage of body fat and a higher proportion of lean mass than they started with. That holds even though their absolute muscle mass dropped.
That’s the opposite of what “losing 45 percent muscle” implies to most readers.
More striking still is what happens to strength and function, the things muscle is actually for.
In a twelve-month real-world study of semaglutide, participants lost some skeletal muscle mass on paper. Yet their handgrip strength increased, and the prevalence of sarcopenic obesity fell. In the large tirzepatide trial, participants reported significantly improved physical function despite the lean-mass changes.
If people are getting measurably stronger and moving better, the raw muscle-loss percentage is not capturing the thing that matters. Muscle is a means to function, and function generally improved.
None of this means the muscle loss is nothing.
For older adults, for people already low on muscle, and for anyone eating too little protein, the picture is different. Losing lean tissue on top of age-related decline is a real concern worth taking seriously. The point is narrower. The headline number vastly overstates the alarm for the average person.
The supplement industry has built a category on that alarm rather than the data.
What Actually Protects Muscle — and What Doesn’t
Suppose you are in the group with genuine reason to protect muscle. Here the data are refreshingly clear, and inconvenient for the supplement aisle.
The two interventions with strong evidence are eating enough protein and doing resistance training. Studies of people who preserved lean tissue on these drugs point to the same combination. It’s adequate protein, often around 1.2 to 1.6 grams per kilogram of body weight, plus lifting something heavy a few times a week. That’s it.
Those two levers do most of the work, and the research on people who successfully hold onto muscle keeps returning to them.
Notice what’s absent from that list.
The specialized “muscle-preservation” capsules aren’t the hero of any of these studies. Protein is genuinely useful, but only as a way to hit a target that a suppressed appetite makes hard to reach through food.
It’s not a magic compound.
A protein supplement is a convenience for meeting a number, and a reasonable one. The broader constellation of GLP-1 muscle-support pills is mostly selling access to a solution you already have. It’s chicken, Greek yogurt, and a set of dumbbells. The most effective muscle support in the GLP-1 era isn’t sold in the supplement aisle at all. It’s a barbell.
The Second Scary Number: Side Effects
The other pillar holding up the GLP-1 support market is side effects, and it follows the same pattern: a frightening headline resting on reassuring fine print.
The headline is that nausea affects a huge share of users, around 44 percent in the STEP 1 trial.
Digestive complaints, nausea, vomiting, diarrhea, and constipation, are indeed the most common effects of these drugs. On its face, that sounds like a population in constant misery, ripe for anti-nausea supplements, digestive aids, and electrolyte rescue formulas.
Now the fine print.
Across the STEP trials, 99.5 percent of gastrointestinal side effects were non-serious, and 98.1 percent were mild to moderate. They were typically transient, clustered during the dose-escalation period, and faded once people reached a stable maintenance dose.
Only about 4.3 percent of participants stopped treatment because of them, meaning more than 95 percent of people who experienced side effects kept going. The scary 44 percent includes everyone who felt queasy even once across more than a year.
It is not a snapshot of chronic suffering.
The Detail That Undercuts the Whole Pitch
There’s one more finding that deserves to be better known, because it quietly dismantles a common assumption.
Many people believe, and some marketing implies, that the discomfort is doing the work. The idea is that appetite loss and nausea are how the drug reduces eating.
If that were true, blunting side effects might blunt results. But a mediation analysis across the STEP trials found the opposite. Of the substantial extra weight loss semaglutide produced over placebo, less than one percentage point was attributable to gastrointestinal side effects. The drug’s effect on weight was essentially independent of whether you felt sick.
This matters for the supplement question in two directions.
It means side-effect-management products, if they work, won’t sabotage your results, which is reassuring. But it also means the side effects are a transient, manageable nuisance rather than a central feature of treatment. That further shrinks the case for building an ongoing supplement regimen around them.
For most people, gentle, temporary measures during the dose-escalation weeks, plus a conversation with the prescriber if symptoms are severe, cover it.
What GLP-1 Support Is Actually Worth Taking
Strip away the alarm, and a short, unglamorous list survives the evidence.
Protein is worth prioritizing, mostly from food, with a supplement as a practical tool to hit a target that reduced appetite makes hard. Basic attention to hydration is sensible, as is watching the micronutrients that can fall short when you eat much less, such as vitamin D, B12, and iron.
Actual bloodwork, not a marketing checklist, should guide that.
During the first weeks of dose escalation, simple measures for transient nausea or constipation are reasonable. And resistance training, which costs nothing and outperforms every capsule, belongs at the top of the list even though no one profits from recommending it.
Everything beyond that thins out quickly.
The elaborate “GLP-1 support stacks” promising to counteract the medication are mostly answering a problem the data describe as milder and more self-limiting than advertised.
Bottom Line
The GLP-1 support industry is a case study in how real statistics get weaponized once you remove their context.
Yes, up to 45 percent of weight lost is lean mass, but that’s normal for rapid weight loss; body composition improves anyway, and strength often rises.
Yes, nausea is common, but it’s overwhelmingly mild, transient, and irrelevant to how well the drug works.
The interventions actually supported by evidence, protein and resistance training, are cheap, dull, and largely unsellable. The science here is genuinely more nuanced than the marketing, and the nuance points somewhere uncomfortable for an entire product category.
Most people on these drugs need far less “support” than they’re being sold.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024;26(Suppl 3):16-27.
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022;24(1):94-105.
- Élan Clinic / STEP trial pooled data summary. Permanent discontinuation due to GI adverse events occurred in 4.3% of semaglutide participants versus 0.8% on placebo (STEP 1-4).
- SEMALEAN Study. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity. 2025.
- SURMOUNT-1 body composition and physical function analyses (tirzepatide).
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. PMC. 2025.
- Innova Market Insights, via Nutrition Insight. GLP-1 companion supplement market growth. 2026.
